Jessica Altamirano, NP
Family · Las Cruces, NMNPI 1215696588
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,828 of the $4,704 with a category attached, or 81.4%. 24 manufacturers reported payments, led by Axonics, Inc. at 49.2% of the total. Among family clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 116 payments — averaging $40.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$2K
- Sumitomo Pharma America, Inc.$525
- Boston Scientific$245
- Merck$178
- Progenics Pharmaceuticals, Inc.$146
- Bayer$131
- plus $1K from 18 others
What the payments were for
- Travel & lodging$77717%
- Food & beverage$3,82881%
- Education$992%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 39 | $2,314 |
| Sumitomo Pharma America, Inc. | 19 | $525 |
| Boston Scientific | 6 | $245 |
| Merck | 7 | $178 |
| Progenics Pharmaceuticals, Inc. | 3 | $146 |
| Bayer | 4 | $131 |
| Astellas Pharma US Inc | 2 | $119 |
| AbbVie | 5 | $116 |
| Johnson & Johnson | 3 | $116 |
| Gilead | 2 | $110 |
| Vifor Pharma, Inc. | 1 | $107 |
| Medtronic | 4 | $88 |
| Calyxo, Inc. | 2 | $82 |
| Procept Biorobotics Corporation | 2 | $77 |
| Olympus America Inc. | 3 | $74 |
| 180 Medical, Inc. | 3 | $60 |
| Novartis | 2 | $57 |
| Tolmar, Inc. | 3 | $46 |
| Urogen Pharma, Inc. | 1 | $34 |
| Myriad Genetic Laboratories, Inc. | 1 | $20 |
| Laborie Medical Technologies Corp. | 1 | $17 |
| Hollister Incorporated | 1 | $15 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,704 in reported general payments places this provider in the 95th percentile of 1,080 family providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 86 | $100,007 |
| GemtesaVibegron | 31 | $42,136 |
| PremarinEstrogens, Conjugated | 36 | $15,800 |
| Solifenacin Succinate | 168 | $11,334 |
| Trospium Chloride | 104 | $9,336 |
| Tamsulosin Hcl | 448 | $8,073 |
| Estradiol | 82 | $4,398 |
| NitrofurantoinNitrofurantoin Macrocrystal | 104 | $4,058 |
| Oxybutynin Chloride ErOxybutynin Chloride | 167 | $3,678 |
| Finasteride | 210 | $3,195 |
| Trimethoprim | 42 | $3,066 |
| Tolterodine Tartrate ErTolterodine Tartrate | 28 | $2,561 |
| Testosterone | 17 | $2,359 |
| Cephalexin | 128 | $2,290 |
| Doxazosin Mesylate | 102 | $1,599 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $119 | $100,00786 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $525 | $42,13631 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,080 family providers in New Mexico.
Other family in Las Cruces
- Jamie LujanLas Cruces$14K
- Joleen LeszczynskiLas Cruces$8K
- Deborah PachecoLas Cruces$6K
- Angelina CarverLas Cruces$5K
- Russell CoryellLas Cruces$5K
- Laura OrtegaLas Cruces$4K
- Rachel SaavedraLas Cruces$3K
- Thomas HaythLas Cruces$3K
- David SeiterFarmington$194K
- Carol HollandRoswell$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.